Self-sacrificial MOFs for ultra-long controlled release of bisphosphonate anti-osteoporotic drugs
M Vassaki, KE Papathanasiou… - Chemical …, 2020 - pubs.rsc.org
In this paper we report drug delivery systems that are based on phosphonate MOFs. These
employ biologically-acceptable metal ions (eg Ca2+ and Mg2+) and several anti …
employ biologically-acceptable metal ions (eg Ca2+ and Mg2+) and several anti …
Effectiveness of oral bisphosphonates in reducing fracture risk among oral glucocorticoid users: three matched cohort analyses
MA Amiche, LE Lévesque, T Gomes… - Journal of Bone and …, 2018 - academic.oup.com
The benefit of oral bisphosphonates in reducing fracture risk in glucocorticoid‐induced
osteoporosis is controversial. We aimed to estimate the effectiveness of oral …
osteoporosis is controversial. We aimed to estimate the effectiveness of oral …
Time trends in oral bisphosphonate initiation in Ontario, Canada over 20 years reflect drug policy and healthcare delivery changes
Characteristics of patients starting oral bisphosphonate therapy changed over time,
reflecting trends in osteoporosis management (eg, new drugs to market), and general …
reflecting trends in osteoporosis management (eg, new drugs to market), and general …
Brand and generic use of inhalation medication and frequency of switching in children and adults: a population-based cohort study
M Engelkes, JC van Blijderveen, JA Overbeek… - Journal of …, 2018 - Taylor & Francis
Background: The expiration of patents of brand inhalation medications and the ongoing
pressure on healthcare budgets resulted in a growing market for generics. Aim: To study the …
pressure on healthcare budgets resulted in a growing market for generics. Aim: To study the …
Urban–rural differences in the uptake of new oral bisphosphonate formulations
R Jandoc, M Mamdani, LE Lévesque… - Archives of …, 2016 - Springer
We identified significantly slower uptake, and consistently lower proportions of new oral
bisphosphonate formulations dispensed in rural regions compared to urban regions of …
bisphosphonate formulations dispensed in rural regions compared to urban regions of …
Medication persistence, duration of treatment, and treatment-switching patterns among Canadian patients taking once-daily extended-release methylphenidate …
L Park-Wyllie, J Van Stralen, D Almagor… - Clinical Therapeutics, 2016 - Elsevier
Purpose We conducted a retrospective cohort study to compare medication use patterns of a
long-acting extended-release methylphenidate (Osmotic Release Oral System [OROS®] …
long-acting extended-release methylphenidate (Osmotic Release Oral System [OROS®] …
[BOOK][B] Oral Glucocorticoids: Fracture Risk and Benefit of Osteoporosis Pharmacotherapy
MA Amiche - 2017 - search.proquest.com
Oral glucocorticoids are potent anti-inflammatory and immunosuppressant agents used to
treat and control several conditions. However, oral glucocorticoid exposure leads to an …
treat and control several conditions. However, oral glucocorticoid exposure leads to an …
Understanding Patterns and Estimating Relative Effects of Long-term Bisphosphonate Therapy and Drug Holidays
KN Hayes - 2021 - search.proquest.com
Osteoporosis is a disease of low bone mass that causes debilitating fractures. Oral
bisphosphonates (alendronate, risedronate, and etidronate) are first-line therapy for …
bisphosphonates (alendronate, risedronate, and etidronate) are first-line therapy for …
